Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05128500
Other study ID # MIRAI CLH-1
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date July 12, 2019
Est. completion date July 31, 2025

Study information

Verified date February 2024
Source Permedica spa
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study is conducted in order to evaluate the effectiveness of the primary total shoulder arthroplasty with the Permedica's MIRAI Modular Shoulder Prosthesis System on the general population of patients who are about to undergo this surgery for every indication. Patients requiring a revision shoulder arthroplasty will not be enrolled. The effectiveness will be evaluated in terms of recovery of shoulder function and stability of the prosthetic implant. The incidence of complications, adverse and serious adverse events will also be studied. Additional study aim is to evaluate a medium/long term survival of the prosthesis. The duration of the study per single subject is 5 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 200
Est. completion date July 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - both genders - at least 18 years old of age - undergoing a primary total shoulder arthroplasty with MIRAIĀ® Prosthesis System (anatomic or reverse, stemless or stemmed). - Signed informed consent Exclusion Criteria: - Patients requiring a revision shoulder arthroplasty - Persistent chronic or acute infections and all septic conditions - Persistent osteomyelitis local or systemic - Allergy or hypersensitivity to the substances contained in the materials of the implanted components - Acute or chronic neurological and/or musculoskeletal impairment which compromises the shoulder joint function such as an axillary nerve injury affecting the deltoid muscle - Inadequate bone structure which cannot guarantee stability to the prosthetic components - Several vascular, nerve or muscular disorders, which compromise related extremities - Marked osteoporosis, osteomalacia - Hypotrophy of the periarticular soft tissues - Dysmetabolic diseases such as, for example, kidney failure or systemic diseases - Muscular insufficiency - Active neoplastic or metastatic diseases - Any other clinical or physical condition that can invalidate the surgery, the rehabilitation or the prosthesis stability - Patient unwilling or unable to undergo the rehabilitation or to return to follow-up visits - Women in pregnancy, childbearing potential or breastfeeding - Involvement in other ongoing studies or clinical trial.

Study Design


Intervention

Procedure:
Total Shoulder Arthroplasty with Permedica's MIRAI
Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System

Locations

Country Name City State
Germany go:h - Gelenkchirurgie Orthopädie: Hannover Hanover
Germany Krankenhaus Reinbek St. Adolf-Stilt Reinbek
Italy ULSS 1 Dolomiti - Presidio Ospedaliero Santa Maria del Prato di Feltre Feltre
Switzerland Orthopädische Klinik Luzern - OKL Luzern

Sponsors (1)

Lead Sponsor Collaborator
Permedica spa

Countries where clinical trial is conducted

Germany,  Italy,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical outcome: Change of shoulder function Change of "American Shoulder and Elbow Surgeons" (ASES) Score. Total score 0-100 ASES points, 0 = worse pain and functional loss/disability. 5 years
Primary Clinical outcome: Change of shoulder function Change of "Disabilities of the Arm, Shoulder and Hand" (DASH) Score. A higher score indicates greater disability. DASH disability/symptom score = [(sum of n responses) - 1]/n x 25, where n is equal to the number of completed responses. 5 years
Primary Clinical outcome: Change of shoulder function Change of Constant Score. Total score 0-100 Constant points, 0 = worse outcome and functional loss/disability; 100 = better outcome, shoulder function improvement. 5 years
Primary Clinical outcome: Change of shoulder function Change of active Range of Motion (ROM) 5 years
Secondary Radiological outcome: Radiological implant stability Presence of Radiolucent Lines and other radiological signs of instability 5 years
Secondary Radiological outcome: Radiological implant stability Presence of Radiolucent Lines and other radiological signs of instability 2 years
Secondary Safety Outcome Incidence of adverse events and complications 5 years
Secondary Implant survival rate Rate of revisions. Survival estimated with Kaplan-Meier method. 5 years
Secondary Implant survival rate Implant failures. Survival estimated with Kaplan-Meier method. 2 years
See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism